课题基金 / 基金详情

University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)

University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
宾夕法尼亚大学神经科学临床试验卓越网络中心 (NeuroNEXT)
批准号:
9983187
负责人:
Brenda Banwell
金额:
$29.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-15 至 2023-06-30

项目摘要

项目成果

Brenda Banwell的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The goal of the proposed Penn Center for Excellence in Neuroscience Clinical Trials (Penn NeuroNEXT) is to bring together and optimize the contributions of a large group of experienced investigators focused in the clinical neurosciences at the University of Pennsylvania Perelman School of Medicine (UPennSOM), across four major teaching hospitals: the Hospital of the University of Pennsylvania (HUP), the Children's Hospital of Philadelphia (CHOP), Pennsylvania Hospital (PAH) and Penn Presbyterian Medical Center (PPMC). UPennSOM has long been a leading Center for clinical research in the neurosciences, and internationally recognized leaders in neurology, neurosurgery, neuroradiology, and psychiatry have a strong track record of collaboration, evidenced by existing multiple program projects, collaborative agreements, successful participation in federally and industry-sponsored multi-center clinical trials, and a large number of investigator- initiated studies. The expertise of Penn NeuroNEXT investigators covers the lifespan, and they have been leading contributors to our understanding of and development of innovative therapies for neurological disorders from infancy through old age. Penn NeuroNEXT will leverage existing clinical research infrastructure and resources to efficiently Penn NeuroNEXT will contribute to NeuroNEXT by leveraging the expertise of senior leaders in the clinical neurosciences at Penn, as well as the enthusiasm and hard work from a large number of ambitious trainees and junior faculty. These goals are operationalized through the following three Specific Aims: Specific Aim 1: To be an outstanding enrolling site for NeuroNEXT trials. Penn NeuroNEXT will participate in a minimum of 4 NeuroNEXT clinical trials over the next 5 years. We intend to meet or exceed recruitment and retention goals. Specific Aim 2: To optimize efficiency of clinical research in neurosciences at UPennSOM. Penn NeuroNEXT will closely monitor progress of all NeuroNEXT trials, from site qualification, IRB submission, staff training, participant recruitment and retention, data quality assessment, and study closeout. Barriers to success will be identified early, and the experience and institutional influence of Penn NeuroNEXT leadership will be leveraged to overcome such barriers. We will insure that all ancillary services needed for successful participation in Network trials are available for each trial. These include the Investigational Drug Service (IDS), Center for Clinical Epidemiology and Biostatistics, Neuroradiology, Pathology and Laboratory Medicine. Specific Aim 3: To promote career enhancement of early stage clinical investigators. The University of Pennsylvania and our four hospitals are recognized as leading training centers in the clinical neurosciences, and we have been particularly successful in attracting talented young people interested in obtaining the necessary experience for launching academic careers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
  • 批准号:
    10458532
  • 项目类别:
  • 资助金额:
    $29.49万
  • 财政年份:
    2018
  • 负责人:
    Brenda Banwell
  • 依托单位:
University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
  • 批准号:
    10188660
  • 项目类别:
  • 资助金额:
    $29.49万
  • 财政年份:
    2018
  • 负责人:
    Brenda Banwell
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: